Advances in the diagnosis and treatment of Clostridium difficile infections review-article

Emerging Microbes and Infections

Volumn 7, Issue 1, 2018, Pages

  Peng, Zhong ^a   Ling, Lifen ^b,c   Stratton, Charles W ^d   Li, Chunhui ^e   Polage, Christopher R ^f   Wu, Bin ^a   Tang, Yi Wei ^c,g  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^b THE EIGHTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CENTRAL SOUTH UNIVERSITY   (China)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEZLOTOXUMAB; CADAZOLID; RIDINILAZOLE; SUROTOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIUM CULTURE; CLOSTRIDIUM DIFFICILE INFECTION; CYTOTOXICITY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG APPROVAL; DRUG USE; GOLD STANDARD; HUMAN; INFECTION PREVENTION; LABORATORY DIAGNOSIS; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; ANIMAL; CLOSTRIDIUM INFECTION; DIARRHEA; DRUG EFFECT; GENETICS; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; HUMANS;

EID: 85041951312     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/s41426-017-0019-4     Document Type: Review

References (109)

1. Leffler, D. A. & Lamont, J. T. Clostridium difficile infection. N. Engl. J. Med. 372, 1539-1548 (2015).
2. Napolitano, L. M. & Edmiston, C. E. Jr. Clostridium difficile disease: diagnosis, pathogenesis, and treatment update. Surgery 162, 325-348 (2017).
3. Shin, J. H., Chaves-Olarte, E. & Warren, C. A. Clostridium difficile infection. Microbiol. Spectr. 4, https://doi.org/10.1128/microbiolspec.EI10-0007-2015 (2016).
4. Lessa, F. C., Gould, C. V. & McDonald, L. C. Current status of Clostridium difficile infection epidemiology. Clin. Infect. Dis. 55(Suppl. 2), S65-S70 (2012).
5. Cohen, S. H. et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31, 431-455 (2010).
6. Bauer, M. P., Kuijper, E. J. & van Dissel, J. T. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 15, 1067-1079 (2009).
7. Debast, S. B., Bauer, M. P. & Kuijper, E. J. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 20(Suppl. 2), 1-26 (2014).
8. Spigaglia, P. Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther. Adv. Infect. Dis. 3, 23-42 (2016).
9. Peng, Z. et al. Update on antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing. J. Clin. Microbiol. 55, 1998-2008 (2017).
10. Crobach, M. J. et al European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 22(Suppl. 4), S63-S81 (2016).
11. Gerding, D. N., File, T. M. Jr & McDonald, L. C. Diagnosis and treatment of Clostridium difficile infection. Infect. Dis. Clin. Pract. 24, 3-10 (2016).
12. Carroll, K. C. & Bartlett, J. G. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu. Rev. Microbiol. 65, 501-521 (2011).
13. Huang, B. et al. Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool. J. Clin. Microbiol. 52, 1105-1111 (2014).
14. Jin, D. et al. Molecular epidemiology of Clostridium difficile infection in hospitalized patients in Eastern China. J. Clin. Microbiol. 55, 801-810 (2017).
15. Chow, W. H. et al. Application of isothermal helicase-dependent amplification with a disposable detection device in a simple sensitive stool test for toxigenic Clostridium difficile. J. Mol. Diagn. 10, 452-458 (2008).
16. Ryder, A. B. et al. Assessment of Clostridium difficile infections by quantitative detection of tcdB toxin by use of a real-time cell analysis system. J. Clin. Microbiol. 48, 4129-4134 (2010).
17. Murad, Y. M. et al. False negative results in Clostridium difficile testing. BMC Infect. Dis. 16, 430 (2016).
18. Merz, C. S. et al. Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens. J. Clin. Microbiol. 32, 1142-1147 (1994).
19. Kociolek, L. K. Strategies for optimizing the diagnostic predictive value of Clostridium difficile molecular diagnostics. J. Clin. Microbiol. 55, 1244-1248 (2017).
20. Planche, T. & Wilcox, M. H. Diagnostic pitfalls in Clostridium difficile infection. Infect. Dis. Clin. North Am. 29, 63-82 (2015).
21. Barbut, F. et al. Does a rapid diagnosis of Clostridium difficile infection impact on quality of patient management? Clin. Microbiol. Infect. 20, 136-144 (2014).
22. Dunwoody, R., Steel, A., Landy, J. & Simmonds, N. Clostridium difficile and cystic fibrosis: management strategies and the role of faecal transplantation. Paediatr. Respir. Rev. doi:10.1016/j.prrv.2017.03.003 (2017).
23. Burnham, C. A. & Carroll, K. C. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin. Microbiol. Rev. 26, 604-630 (2013).
24. Surawicz, C. M. et al Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108, 478-498 (2013).
25. Schroeder, L. F., Robilotti, E., Peterson, L. R., Banaei, N. & Dowdy, D. W. Economic evaluation of laboratory testing strategies for hospital-associated Clostridium difficile infection. J. Clin. Microbiol. 52, 489-496 (2014).
26. Chen, S., Gu, H., Sun, C., Wang, H. & Wang, J. Rapid detection of Clostridium difficile toxins and laboratory diagnosis of Clostridium difficile infections. Infection 45, 255-262 (2017).
27. Gerding, D. N., Johnson, S., Rupnik, M. & Aktories, K. Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes 5, 15-27 (2014).
28. Gilligan, P. H. Optimizing the laboratory diagnosis of Clostridium difficile infection. Clin. Lab. Med. 35, 299-312 (2015).
29. Smits, W. K., Lyras, D., Lacy, D. B., Wilcox, M. H. & Kuijper, E. J. Clostridium difficile infection. Nat. Rev. Dis. Primers 2, 16020 (2016).
30. Martinez-Melendez, A. et al. Current knowledge on the laboratory diagnosis of Clostridium difficile infection. World J. Gastroenterol. 23, 1552-1567 (2017).
31. Deshpande, A. et al. Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile Infection: a meta-analysis. Clin. Infect. Dis. 53, e81-e90 (2011).
32. Stockmann, C. et al. How well does physician selection of microbiologic tests identify Clostridium difficile and other pathogens in paediatric diarrhoea? Insights using multiplex PCR-based detection. Clin. Microbiol. Infect. 21, 179.e9-179. e15. (2015).
33. Beckmann, C., Heininger, U., Marti, H. & Hirsch, H. H. Gastrointestinal pathogens detected by multiplex nucleic acid amplification testing in stools of pediatric patients and patients returning from the tropics. Infection 42, 961-970 (2014).
34. Polage, C. R. et al. Outcomes in patients tested for Clostridium difficile toxins. Diagn. Microbiol. Infect. Dis. 74, 369-373 (2012).
35. Polage, C. R. et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern. Med. 175, 1792-1801 (2015).
36. Kociolek, L. K. et al. Impact of a healthcare provider educational intervention on frequency of Clostridium difficile polymerase chain reaction testing in children: a segmented regression analysis. J. Pediatr. Infect. Dis. Soc. 6, 142-148 (2017).
37. Leslie, J. L., Cohen, S. H., Solnick, J. V. & Polage, C. R. Role of fecal Clostridium difficile load in discrepancies between toxin tests and PCR: is quantitation the next step in C. difficile testing?. Eur. J. Clin. Microbiol. Infect. Dis. 31, 3295-3299 (2012).
38. Truong, C. Y. et al. Real-time electronic tracking of diarrheal episodes and laxative therapy enables verification of Clostridium difficile clinical testing criteria and reduction of Clostridium difficile infection rates. J. Clin. Microbiol. 55, 1276-1284 (2017).
39. Senchyna, F. et al. Clostridium difficile PCR cycle threshold predicts free toxin. J. Clin. Microbiol. 55, 2651-2660 (2017).
40. Avila, M. B., Avila, N. P. & Dupont, A. W. Recent advances in the diagnosis and treatment of Clostridium difficile infection. F1000Research 5, https://doi.org/10.12688/f1000research.7109.1 (2016).
41. Manzoor, S. E. et al. Extended multilocus variable-number tandem-repeat analysis of Clostridium difficile correlates exactly with ribotyping and enables identification of hospital transmission. J. Clin. Microbiol. 49, 3523-3530 (2011).
42. Killgore, G. et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J. Clin. Microbiol. 46, 431-437 (2008).
43. Lemee, L. et al. Multilocus sequence analysis and comparative evolution of virulence-associated genes and housekeeping genes of Clostridium difficile. Microbiology 151, 3171-3180 (2005).
44. Lemee, L., Dhalluin, A., Pestel-Caron, M., Lemeland, J. F. & Pons, J. L. Multilocus sequence typing analysis of human and animal Clostridium difficile isolates of various toxigenic types. J. Clin. Microbiol. 42, 2609-2617 (2004).
45. van den Berg, R. J., Schaap, I., Templeton, K. E., Klaassen, C. H. & Kuijper, E. J. Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis. J. Clin. Microbiol. 45, 1024-1028 (2007).
46. Franzosa, E. A. et al. Sequencing and beyond: integrating molecular 'omics' for microbial community profiling. Nat. Rev. Microbiol. 13, 360-372 (2015).
47. Didelot, X. et al Microevolutionary analysis of Clostridium difficile genomes to investigate transmission. Genome Biol. 13, R118 (2012).
48. He, M. et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat. Genet. 45, 109-113 (2013).
49. Eyre, D. W. et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N. Engl. J. Med. 369, 1195-1205 (2013).
50. Kumar, N. et al. Genome-based infection tracking reveals dynamics of Clostridium difficile transmission and disease recurrence. Clin. Infect. Dis. 62, 746-752 (2016).
51. Eyre, D. W. et al. Comparison of control of Clostridium difficile infection in six english hospitals using whole-genome sequencing. Clin. Infect. Dis. 65, 433-441 (2017).
52. Feher, C., Soriano, A. & Mensa, J. A review of experimental and off-label therapies for Clostridium difficile infection. Infect. Dis. Ther. 6, 1-35 (2017).
53. Kali, A., Charles, M. V. & Srirangaraj, S. Cadazolid: a new hope in the treatment of Clostridium difficile infection. Australas. Med. J. 8, 253-262 (2015).
54. Locher, H. H. et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob. Agents Chemother. 58, 892-900 (2014).
55. Chilton, C. H. et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J. Antimicrob. Chemother. 69, 697-705 (2014).
56. Gerding, D. N. et al. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. J. Antimicrob. Chemother. 71, 213-219 (2016).
57. Knight-Connoni, V., Mascio, C., Chesnel, L. & Silverman, J. Discovery and development of surotomycin for the treatment of Clostridium difficile. J. Ind. Microbiol. Biotechnol. 43, 195-204 (2016).
58. Chilton, C. H. et al. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. J. Antimicrob. Chemother. 69, 2426-2433 (2014).
59. Lee, C. H. et al. Surotomycin versus vancomycin for Clostridium difficile infection: phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial. J. Antimicrob. Chemother. 71, 2964-2971 (2016).
60. Boix, V. et al. Primary outcomes from a phase 3, randomized, double-blind, active-controlled trial of surotomycin in subjects with Clostridium difficile infection. Open Forum Infect. Dis. 4, ofw275 (2017).
61. Leeds, J. A., Sachdeva, M., Mullin, S., Dzink-Fox, J. & Lamarche, M. J. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob. Agents Chemother. 56, 4463-4465 (2012).
62. Sachdeva, M. & Leeds, J. A. Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile. Antimicrob. Agents Chemother. 59, 1252-1257 (2015).
63. Citron, D. M., Tyrrell, K. L., Merriam, C. V. & Goldstein, E. J. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 56, 2493-2503 (2012).
64. Trzasko, A., Leeds, J. A., Praestgaard, J., Lamarche, M. J. & McKenney, D. Efficacy of LFF571 in a hamster model of Clostridium difficile infection. Antimicrob. Agents Chemother. 56, 4459-4462 (2012).
65. Ting, L. S. et al. A first-in-human, randomized, double-blind, placebo-controlled, single-and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers. Antimicrob. Agents Chemother. 56, 5946-5951 (2012).
66. Mullane, K. et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob. Agents Chemother. 59, 1435-1440 (2015).
67. Basseres, E. et al. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J. Antimicrob. Chemother. 71, 1245-1251 (2016).
68. Vickers, R. J. et al. Ridinilazole: a novel therapy for Clostridium difficile infection. Int. J. Antimicrob. Agents 48, 137-143 (2016).
69. Goldstein, E. J., Citron, D. M. & Tyrrell, K. L. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence. Antimicrob. Agents Chemother. 58, 1187-1191 (2014).
70. Vickers, R. J. et al. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect. Dis. 17, 735-744 (2017).
71. Goldberg, E. J. et al. Clostridium difficile infection: a brief update on emerging therapies. Am. J. Health Syst. Pharm. 72, 1007-1012 (2015).
72. Ofosu, A. Clostridium difficile infection: a review of current and emerging therapies. Ann. Gastroenterol. 29, 147-154 (2016).
73. Dieterle, M. G. & Young, V. B. Reducing recurrence of C. difficile infection. Cell 169, 375 (2017).
74. Bartlett, J. G. Bezlotoxumab-a new agent for Clostridium difficile infection. N. Engl. J. Med. 376, 381-382 (2017).
75. Wilcox, M. et al. Bezlotoxumab alone and with actoxumab for prevention of recurrent Clostridium difficile infection in patients on standard of care antibiotics: integrated results of 2 phase 3 studies (MODIFY I and MODIFY II). Open Forum Infect. Dis. 2, 67 (2015).
76. Dzunkova, M. et al. The monoclonal antitoxin antibodies (actoxumab-be-zlotoxumab) treatment facilitates normalization of the gut microbiota of mice with Clostridium difficile infection. Front. Cell. Infect. Microbiol. 6, 119 (2016).
77. Mathur, H., Rea, M. C., Cotter, P. D., Ross, R. P. & Hill, C. The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes 5, 696-710 (2014).
78. Liubakka, A. & Vaughn, B. P. Clostridium difficile infection and fecal microbiota transplant. AACN Adv. Crit. Care 27, 324-337 (2016).
79. Kassam, Z., Lee, C. H., Yuan, Y. & Hunt, R. H. Fecal microbiota transplantation for Clostridium difficileinfection: systematic review and meta-analysis. Am. J. Gastroenterol. 108, 500-508 (2013).
80. Youngster, I. et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312, 1772-1778 (2014).
81. Cohen, N. A. et al. A retrospective comparison of fecal microbial transplantation methods for recurrent Clostridium difficile infection. Isr. Med. Assoc. J. 18, 594-599 (2016).
82. Orenstein, R. et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin. Infect. Dis. 62, 596-602 (2016).
83. Martin, J. & Wilcox, M. New and emerging therapies for Clostridium difficile infection. Curr. Opin. Infect. Dis. 29, 546-554 (2016).
84. Gao, X. W., Mubasher, M., Fang, C. Y., Reifer, C. & Miller, L. E. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus caseiLBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am. J. Gastroenterol. 105, 1636-1641 (2010).
85. Maziade, P. J., Pereira, P. & Goldstein, E. J. A decade of experience in primary prevention of Clostridium difficileinfection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clin. Infect. Dis. 60(Suppl. 2), S144-S147 (2015).
86. Goldenberg, J. Z. et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst. Rev. Cd006095, https://doi.org/10.1002/14651858.CD006095.pub3 (2013).
87. Johnston, B. C. et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann. Intern. Med. 157, 878-888 (2012).
88. Ratsep, M. et al. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection. Anaerobe 47, 94-103 (2017).
89. Pozzoni, P. et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am. J. Gastroenterol. 107, 922-931 (2012).
90. Wullt, M., Hagslatt, M. L. & Odenholt, I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand. J. Infect. Dis. 35, 365-367 (2003).
91. Pochapin, M. The effect of probiotics on Clostridium difficile diarrhea. Am. J. Gastroenterol. 95, S11-S13 (2000).
92. Allen, S. J. et al. A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE). Health Technol. Assess. 17, 1-140 (2013).
93. Allen, S. J. et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 382, 1249-1257 (2013).
94. Villano, S. A., Seiberling, M., Tatarowicz, W., Monnot-Chase, E. & Gerding, D. N. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob. Agents Chemother. 56, 5224-5229 (2012).
95. Nagaro, K. J. et al. Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile. Antimicrob. Agents Chemother. 57, 5266-5270 (2013).
96. Zhang, K. et al. The non-toxigenic Clostridium difficileCD37 protects mice against infection with a BI/NAP1/027 type of C. difficile strain. Anaerobe 36, 49-52 (2015).
97. Gerding, D. N. et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 313, 1719-1727 (2015).
98. Ivarsson, M. E., Leroux, J. C. & Castagner, B. Investigational new treatments for Clostridium difficile infection. Drug Discov. Today 20, 602-608 (2015).
99. Wang, Q., Euler, C. W., Delaune, A. & Fischetti, V. A. Using a novel lysin to help control Clostridium difficile infections. Antimicrob. Agents Chemother. 59, 7447-7457 (2015).
100. Giesemann, T., Guttenberg, G. & Aktories, K. Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology 134, 2049-2058 (2008).
101. Furci, L. et al New role for human alpha-defensin 5 in the fight against hypervirulent Clostridium difficile strains. Infect. Immun. 83, 986-995 (2015).
102. Bender, K. O. et al. A small-molecule antivirulence agent for treating Clostridium difficile infection. Sci. Transl. Med. 7, 306ra148 (2015).
103. Johnson, S. et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin. Infect. Dis. 59, 345-354 (2014).
104. Rodriguez, C., Taminiau, B., Van Broeck, J., Delmee, M. & Daube, G. Clostridium difficilein food and animals: a comprehensive review. Adv. Exp. Med. Biol. 932, 65-92 (2016).
105. Goorhuis, A. et al Clostridium difficile PCR ribotype 078: an emerging strain in humans and in pigs? J. Clin. Microbiol. 46, 1157 (2008).
106. Janezic, S. et al. International Clostridium difficile animal strain collection and large diversity of animal associated strains. BMC Microbiol. 14, 173 (2014).
107. Songer, J. G. & Trinh, H. Isolation of Clostridium difficile from retail meats. In Proc. 2nd International Clostridium difficile Symposium (Maribor, Slovenia, 2007).
108. Knetsch, C. W. et al. Whole genome sequencing reveals potential spread of Clostridium difficile between humans and farm animals in the Netherlands, 2002 to 2011. Eur. Surveill. 19, 20954 (2014).
109. Mc Govern, A. M. et al. Human Clostridium difficile infection caused by a livestock-associated PCR ribotype 237 strain in Western Austrialia. JMM Case Rep. 3, e005062 (2016).